替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究

doi:10.3969/j.issn.1672-5069.2021.03.007

Abstract

Abstract: Objective The purpose of this study was to observe the efficacy of tenofovir disoproxil fumarate and dual immunization regimen in blocking mother-to-child hepatitis B viral transmission in pregnant women with hepatitis B virus (HBV) carrier.Methods 120 HBV carrying pregnant women were admitted to our hospital between December 2016 and September 2019,and were randomly divided into control and observation group. The pregnant women in the control group didn’t receive any antiviral treatment, while those in the observation group were treated with tenofovir disoproxil fumarate at gestational week 26 to 28 until delivery. The newborns were inoculated with dual immunization regimen, e.g. hepatitis B vaccine and hepatitis B immunoglobulin immediately after birth. Serum HBV DNA loads were detected by PCR, and serum HBsAg and HBeAg were assayed by colloidal gold method.Results At delivery, serum ALT level in the observation women was (23.2±3.6)IU/L, not significantly different compared to [(26.9±4.0)IU/L, P>0.05] in the control, serum HBV DNA loads was (3.1±0.7) lg copies/mL, significantly lower than [(5.9±0.8) lg copies/mL, P<0.05] in the control; the Apgar score in the observation new infants was (9.7±0.3), not significantly different compared to [(9.9±0.5), P>0.05] in the control, and the lengths, body masses and head circumferences in the two group newborns were not significantly different (P>0.05); at delivery, six months and twelve months after delivery, the positive HBV infection in the observation infants were 1.7%, 1.7% and 1.7%, not significantly lower than 11.7%, 11.7% and 13.3% (P>0.05) in the control.Conclusion The management of pregnant women with HBV carrier with oral tenofovir disoproxil fumarate and double immunization program in time for newborns could significantly reduce serum HBV loads, and therefore might decrease mother to infant HBV transmission, which needs multi-center investigation.

Key words: Hepatitis B viral carrier, Tenofovir disoproxil fumarate, Dual immunization regimen, Mother-to-child transmission, Blocking

Huang Yongqun, Huang Runqiang, Xiong Ping’an. Efficacy of tenofovir disoproxil fumarate and dual immunization regimen in blocking mother-to-child hepatitis B viral transmission in pregnant women with hepatitis B virus carrier[J]. Journal of Practical Hepatology, 2021, 24(3): 331-334.

References

[1] Terrault N A, Bzowej N H, Chang K M, et al. Aasld guidelines for treatment of chronic hepatitisB. Hepatology, 2016, 63(1): 261-283.
[2]Brown R J, Mcmahon B J, Lok A S, et al. Antiviral therapy in chronic hepatitisB viral infection during pregnancy: a systematic review and meta-analysis. Hepatology, 2016, 63(1): 319-333.
[3] Yi P, Chen R, Huang Y, et al. Management of mother-to-child transmission of hepatitisB virus: propositions and challenges. J Clin Virol, 2016, 77(8): 32-39.
[4] 马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析. 实用肝脏病杂志, 2019, 22(6): 836-839.
[5] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3): 389-400.
[6] 王垒, 范林, 彭贵主, 等. 乙型肝炎免疫球蛋白在肝移植术后乙型肝炎复发防治中的应用. 中华肝胆外科杂志, 2017, 23(7): 494-498.
[7] Eke A C, Eleje G U, Eke U A, et al. HepatitisB immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev, 2017, 2(6): 8545-8545.
[8] Paul R C, Rahman M, Wiesen E, et al. HepatitisB surface antigen seroprevalence among prevaccine and vaccine era children in Bangladesh. Am J Trop Med Hyg, 2018, 99(3): 764-771.
[9] Mccormick C A, Mccormick P A. Prevention of mother-to-child transmission in patients with chronic hepatitisB virus infection and high viral loads. Iran Med J, 2018, 111(10): 831-831.
[10] 陈欣, 陈立冬, 李庭红.替诺福韦酯治疗多重耐药的乙型肝炎肝硬化患者疗效初步研究. 实用肝脏病杂志, 2018, 21(5): 681-684.
[11] Agarwal K, Brunetto M, Seto W K, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4): 672-681.
[12] Chen J Z, Liao Z W, Huang F L, et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitisB in pregnancies with high viral load. Sci Rep, 2017, 7(1): 4132-4132.
[13] Chan H L, Fung S, Seto W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195.
[14] Buti M, Gane E, Seto W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206.
[15] Wang M, Bian Q, Zhu Y, et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitisB transmission in mothers with high viral load. Aliment Pharmacol Ther, 2019, 49(2): 211-217.
[16] Zeng J, Zheng C, Li H.Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore), 2019, 98(14): 15092-15092.
[17] Nakano L A, Katayose J T, Abreu R M, et al. Assessment of the prevalence of vertical hepatitisB transmission in two consecutive generations. Rev Assoc Med Bras, 2018, 64(2): 154-158.
[18] Weis N, Cowan S, Hallager S, et al. Vertical transmission of hepatitisB virus during pregnancy and delivery in Denmark. Scand J Gastroenterol, 2017, 52(2): 178-184.
[19] Dionne-Odom J, Njei B, Tita A. Elimination of vertical transmission of hepatitisB in Africa: a review of available tools and new opportunities. Clin Ther, 2018, 40(8): 1255-1267.
[20] Sun W, Zhao S, Ma L, et al. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol, 2017, 17(1): 51-51.
[21] 毛创杰, 胡蓉, 曾义岚, 等.替诺福韦酯对四川地区妊娠中期高HBV载量慢性乙型肝炎母婴阻断的疗效 . 中华实验和临床感染病杂志(电子版), 2019, 13(6): 485-490.

Efficacy of tenofovir disoproxil fumarate and dual immunization regimen in blocking mother-to-child hepatitis B viral transmission in pregnant women with hepatitis B virus carrier

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hanbai Yila, Suo Shuyi, Wei Dongmei, et al. Efficacy and safety of tenofovir disoproxil fumarate and telbivudine on blocking mother-to-child transmission of hepatitis B virus infection [J]. Journal of Practical Hepatology, 2021, 24(2): 192-195.
[2]	Zhou Juan, Liu Yuehe, Wang Chuntong. Efficacy of telbivudine and tenofovir in blocking mother-to-infant transmission of hepatitis B virus in pregnant women with high serum HBV DNA loads [J]. Journal of Practical Hepatology, 2020, 23(6): 805-808.
[3]	Yu Jiao, Chen Jixiu, Xue Jianya, et al.. Impact ofserum cytokines on maternal-infant transmission of hepatitis B virus in HBsAg positive women [J]. Journal of Practical Hepatology, 2020, 23(5): 630-633.
[4]	Dong Jing,Liu Longmei,Chen Zhaolin,et al.. Efficacy of tenofovir disoproxil fumarate and double plasma molecular absorb system plus plasma exchange in treatment of patients with HBV-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2020, 23(5): 687-690.
[5]	Zhao Lei, Li Xiaodan, Liu Miao. Efficacy and risk analysis of lamivudine and telbivudine in blockingmother-to-child intrauterine infection of hepatitis B virus [J]. Journal of Practical Hepatology, 2020, 23(4): 496-499.
[6]	Fang Lijuan, Wu Xiongfei. Application ofentecavir in the treatment of patients with hepatitis B virus carrier and pulmonary tuberculosis during antituberculotic therapy [J]. Journal of Practical Hepatology, 2020, 23(3): 340-343.
[7]	Fan Ling, Yang Jun, Ji Fengbing, et al. Efficacy of telbivudine on viral load loss and mother-to-child transmission in pregnant women with chronic hepatitis B viral carrier [J]. Journal of Practical Hepatology, 2020, 23(2): 179-182.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Yang Ruixi, Liu Mingxin, Chen Lingxi. Efficacy and safety of tenofovir disoproxil fumarate and entecavir in the treatment of chronic hepatitis B patients with viral DNA polymerase 204 site mutation infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 349-352.
[11]	Ding Yang, Dou Xiaoguang.. How to achieve zero mother-to-child transmission of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 4-5.
[12]	Wang Qi, Xie Wen.. Screening and management of pregnant women with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 9-12.
[13]	Xu Guorong, Chai Lili.. Efficacy of combination inoculation of hepatitis B vaccine and hepatitis B immunoglobulin on blocking mother-to-child transmission of hepatitis B virus infection in newborn with serum HBsAg/HBeAg-positive mothers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 851-854.
[14]	Zhou Zhiling, Yin Qian.. Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 717-720.
[15]	Bea Abduk Youmu, Zhang Yuexin.. Inoculation of hepatitis B vaccine and hepatitis B immunoglobulin in blocking hepatitis B viral infection in infants from serum HBsAg positive mothers Pauisham Ababackley [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 481-482.